Immuno-Oncology

Joshua Bauml, MD, assistant professor, Perelman School of Medicine, University of Pennsylvania, discusses the next steps for immunotherapy in head and neck cancer.

Loretta Nastoupil, MD, discusses the positive interim analysis and shared her thoughts on areas of future investigation for patients with relapsed follicular lymphoma.

The FDA has approved ipilimumab for the treatment of patients aged ≥12 years with unresectable or metastatic melanoma.

The European Medicines Agency’s Committee for Medicinal Products for Human Use has taken a positive position on indications for atezolizumab in non­-small cell lung cancer and urothelial carcinoma.

Arjun V. Balar, MD, assistant professor of Medicine, Division of Hematology and Oncology, New York University Cancer Institute, NYU Langone Medical Center, discusses combinations with pembrolizumab (Keytruda) for patients with urothelial carcinoma.

Oliver Sartor, MD, a medical oncologist at the Tulane University School of Medicine, discusses the remaining questions with sipuleucel-T (Provenge) in metastatic castration-resistant prostate cancer.

The European Medicines Agency's Committee for Medicinal Products for Human Use has recommended approval of avelumab (Bavencio) for adults with metastatic Merkel cell carcinoma, according to Pfizer and Merck, the codevelopers of the PD-L1 inhibitor.

Joshua Bauml, MD, discusses the current role of immunotherapy in this disease, potential next steps, and unmet needs in HPV-associated head and neck cancer.

Barbara Burtness, MD, professor of Medicine, Yale Cancer Center, discusses immunotherapy combinations for patients with head and neck cancer.

Brian I. Rini, MD, professor of Medicine, Cleveland Clinic, discusses sequencing of immunotherapy combinations for patients with renal cell carcinoma (RCC).

Mathew D. Hellmann, MD, discusses the first report of the randomized expansion cohort from CheckMate-032 in small cell lung cancer.

Results now published in the New England Journal of Medicine show that nivolumab (Opdivo) was not superior for progression-free survival compared with chemotherapy as a first-line treatment for patients with NSCLC.

Barbara Burtness, MD, professor of Medicine, Yale Cancer Center, discusses immunotherapy in patients with head and neck cancer who have radioresistance.

Thomas Powles, MD, Barts Cancer Institute, discusses the combination of bevacizumab (Avastin) and atezolizumab (Tecentriq) versus single-agent atezolizumab versus sunitinib (Sutent), which was studied in the randomized, phase II IMmotion150 trial for patients with metastatic renal cell carcinoma (RCC).

Andrea Apolo, MD, medical oncologist, chief of the bladder cancer section of the Genitourinary Malignancies Branch, National Cancer Institute, discusses the adverse events of the combination of nivolumab (Opdivo) and cabozantinib (Cabometyx) for patients with urothelial carcinoma.

The combination of radiation and immunotherapy is currently enjoying unprecedented attention as a treatment strategy for patients with metastatic cancer.

Joshua Bauml, MD, assistant professor, Perelman School of Medicine, University of Pennsylvania, discusses immunotherapy in head and neck cancer.

Ezra Cohen, MD, associate director, Moores Cancer Center at the University of California, San Diego, discusses immunotherapy combinations in head and neck cancer.